Pakistan Society of Hepatology Guidelines on the Management of Hepatic Encephalopathy
Guidelines for Managing Hepatic Encephalopathy
DOI:
https://doi.org/10.54393/pjhs.v5i05.1499Keywords:
Hepatic Encephalopathy, Hyperammonemia, Liver Cirrhosis, Krebs-Henseleit CycleAbstract
Hepatic Encephalopathy (HE) is one of the major complications in patients with liver cirrhosis. Cirrhosis is a significant health burden worldwide, and due to the increasing population and aging, the burden has increased since 1990. The pathogenesis of HE has been explained by different hypotheses, like astrocyte dysfunction, the ammonia hypothesis, and the GABA hypothesis. Hyperammonemia is the most likely cause of MHE. The breakdown of amines, amino acids, and purines by bacteria in the gastrointestinal tract leads to the production of ammonia. Ammonia is converted to urea in the liver by the Krebs-Henseleit cycle. Guidelines are made to help physicians and gastroenterologists diagnose patients at an early stage of hepatic encephalopathy, and a prompt diagnosis can prevent overt hepatic encephalopathy. Since no previous national guidelines regarding PSE are available, the aim here is to create a unifying guideline regarding the treatment of both overt and covert encephalopathy in a cost-effective manner. The management plan given in these guidelines is flexible and can be changed with more authentic data. We recommended that these guidelines provide a valuable source of information regarding HE in the Pakistani population, its current diagnosis, and its treatment. There is a high cost of treatment for liver diseases, and according to the current available data, we must follow the guidelines of PSH.
References
Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 2020 Mar; 5(3): 245-66. doi: 10.1016/S2468-1253(19)30349-8. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8
Cheemerla S and Balakrishnan M. Global epidemiology of chronic liver disease. Clinical Liver Disease. 2021 May; 17(5): 365-70. doi: 10.1002/cld.1061. DOI: https://doi.org/10.1002/cld.1061
Iqbal M, Clement-Pervaiz MV, Ansari MJ, Pervaiz S, Sheikh S, Katpar S, et al. Proceedings of the 1st Liaquat University of Medical & Health Sciences (LUMHS) International Medical Research Conference. Eur J Med Res. 2017;22:1-20. DOI: https://doi.org/10.1186/s40001-017-0296-3
Shah SM, Mashia SA, Younus MF, Ghauri A, Ejaz R, Alshalabi H et al. Hepatic cirrhosis-disease burden. Journal of Rawalpindi Medical College Student Supplement. 2015; 19(1): 17-20.
Yousaf S, Farhan S, Nadeem MA. Frequency of Minimal Hepatic Encephalopathy in Cirrhotic Patients with Normal Neurological Examination. Age (Years). 2016 Apr; 20(40): 22.
Elwir S and Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. Journal of Clinical and Translational Hepatology. 2017 Jun; 5(2): 142. doi: 10.14218/JCTH.2016.00069. DOI: https://doi.org/10.14218/JCTH.2016.00069
Shiha G and Mousa N. Minimal hepatic encephalopathy: Silent tragedy. In: Georgios Tsoulfas, Luis Rodrigo editors. Liver Diseases Surgery. 2019. doi: 10.5772/intechopen.88231. DOI: https://doi.org/10.5772/intechopen.88231
Bibi M, Ali A, Sahar U, Sajid A, Kumar S, Palh ZA, Naqvi SH, Baloch SK. A CLINICAL MANIFESTATION OF HEPATITIS C AMONG THE POPULATION OF HYDERABAD, PAKISTAN. Pakistan Journal of Biotechnology. 2023 Jun 11;20(02):193-207. DOI: https://doi.org/10.34016/pjbt.2023.20.02.785
Khan RT, Hussain SZ, Shahzad S, Majid Z, Naeem MU, Harjani R, Lail G, Khalid MA, Laeeq SM, Luck NH. Frequency of Non-Alcoholic Fatty Liver Disease Among the Non-Obese Population Presenting to the Gastrointestinal Outpatient Clinic. J Liaquat Natl Hosp. 2024;1:117-21.
Ali B, Salim A, Alam A, Zuberi BF, Ali Z, Azam Z, Kamani L, Farooqi JI, Salih M, Nawaz AA, Chaudhry AA. HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pakistan Journal of Medical Sciences. 2020 Jul;36(5):1117. DOI: https://doi.org/10.12669/pjms.36.5.2407
Tamzaourte M, Rokhsi S, Berrag S, Adioui T. Minimal Hepatic Encephalopathy: Prevalence and Associated Factors. Asian Journal of Research and Reports in Hepatology. 2022 Jan 25;4(1):43-51.
Ghosh J, Ghosh J. Current Management of Hepatic Encephalopathy: A Review Article. Journal for Research in Applied Sciences and Biotechnology. 2023 Sep 23;2(4):170-5. DOI: https://doi.org/10.55544/jrasb.2.4.24
Dharel N and Bajaj JS. Definition and nomenclature of hepatic encephalopathy. Journal of Clinical and Experimental Hepatology. 2015 Mar; 5(1): S37-41. doi: 10.1016/j.jceh.2014.10.001. DOI: https://doi.org/10.1016/j.jceh.2014.10.001
Rafiq Q, Zeeshan M, Mustafa G, Irfan M. Tracheobronchial aspiration affects the outcome of hospitalization among Hepatic Encephalopathy patients. Pakistan Journal of Medical Sciences. 2022 Mar;38(4Part-II):928. DOI: https://doi.org/10.12669/pjms.38.4.5114
Pisarek, W.J.G.R.P.G., Minimal hepatic encephalopathy–diagnosis and treatment. 2021 Dec; 16(4): 311-317. doi: 10.5114/pg.2021.111389. DOI: https://doi.org/10.5114/pg.2021.111389
Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. Journal of Gastroenterology and Hepatology. 2010 Jun; 25(6): 1029-41. doi: 10.1111/j.1440-1746.2010.06318.x. DOI: https://doi.org/10.1111/j.1440-1746.2010.06318.x
Pessidjo Djomatcho L, Kowo MP, Ndam AN, Njonnou SR, Kenfack GU, Andoulo FA et al. Normalisation of the psychometric encephalopathy score within the Cameroonian population. Baseboard Management Controller gastroenterology. 2021 Dec; 21: 1-7. doi: 10.1186/s12876-021-01858-7. DOI: https://doi.org/10.1186/s12876-021-01858-7
Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. Annals of Gastroenterology. 2018 Mar; 31(2): 151. doi: 10.20524/aog.2018.0232. DOI: https://doi.org/10.20524/aog.2018.0232
Gou LB, Zhang W, Guo DJ, Zhong WJ, Wu XJ, Zhou ZM. Aberrant brain structural network and altered topological organization in minimal hepatic encephalopathy. Diagnostic and Interventional Radiology. 2020 May;26(3):255. DOI: https://doi.org/10.5152/dir.2019.19216
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. Journal of Hepatology. 2022 Sep; 77(3): 807-824. doi: 10.1016/j.jhep.2022.06.001. DOI: https://doi.org/10.1016/j.jhep.2022.06.001
Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M et al. The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017 Jul; 66(1): 198-208. doi: 10.1002/hep.29146. DOI: https://doi.org/10.1002/hep.29146
Lauridsen MM, Mikkelsen S, Svensson T, Holm J, Klüver C, Gram J et al. The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention-a pilot study. PLOS One. 2017 Oct; 12(10): e0185412. doi: 10.1371/journal.pone.0185412. DOI: https://doi.org/10.1371/journal.pone.0185412
Thomas S, Fiebig JE, Kuhn EM, Mayer DS, Filbeck S, Schmitz W, Krischke M, Gropp R, Mueller TD. Design of glycoengineered IL-4 antagonists employing chemical and biosynthetic glycosylation. ACS Omega. 2023;8(28). DOI: https://doi.org/10.1021/acsomega.3c00726
Luo M, Ma P, Li L, Cao WK. Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment. The Turkish Journal of Gastroenterology. 2019 May; 30(5): 398. doi: 10.5152/tjg.2019.18226. DOI: https://doi.org/10.5152/tjg.2019.18226
Mehreen N, Aziz B, Taj MK, Saleem M, Taj G, Zafar U. Hepatic encephalopathy and its management. 2022 June; 20(6): 45-64. doi:10.12692/ijb/20.6.45-64.
Edward Ukamaka C, Nwanjo Harrison U, Nwosu Dennis C. Studies on Acute Phase Inflamatory Proteins of Type 2 Diabetics in Owerri. 2019 Oct; 4(10): 324-332. doi: 10.36348/SJBR.2019.v04i10.002. DOI: https://doi.org/10.36348/SJBR.2019.v04i10.002
Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM et al. Evaluation of IL‐6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients with Liver Cirrhosis. Hepatology Communications. 2022 May; 6(5): 1113-22. doi: 10.1002/hep4.1883. DOI: https://doi.org/10.1002/hep4.1883
Akhtar AJ, Alamy ME, Yoshikawa TT. Extrahepatic conditions and hepatic encephalopathy in elderly patients. The American Journal of the Medical Sciences. 2002 Jul; 324(1): 1-4. doi: 10.1097/00000441-200207000-00001. DOI: https://doi.org/10.1097/00000441-200207000-00001
Amodio P. Hepatic encephalopathy: Diagnosis and management. Liver International. 2018 Jun; 38(6): 966-75. doi: 10.1111/liv.13752. DOI: https://doi.org/10.1111/liv.13752
Weissenborn K. Challenges in diagnosing hepatic encephalopathy. Neurochemical Research. 2015 Feb; 40: 265-73. doi: 10.1007/s11064-014-1416-x. DOI: https://doi.org/10.1007/s11064-014-1416-x
Díaz-Fontenla F, Castillo-Pradillo M, Díaz-Gómez A, Ibañez-Samaniego L, Gancedo P, Guzmán-de-Villoria JA et al. Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism. World Journal of Gastroenterology. 2017 Jul; 23(28): 5246. doi: 10.3748/wjg.v23.i28.5246. DOI: https://doi.org/10.3748/wjg.v23.i28.5246
Wijdicks EF. Hepatic Encephalopathy. The New England Journal of Medicine. 2016 Oct; 375(17): 1660-1670. doi: 10.1056/NEJMra1600561. DOI: https://doi.org/10.1056/NEJMra1600561
Gluud LL, Vilstrup H, Morgan MY. Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews. 2016; 5: CD003044. doi:10.1002/14651858.CD003044. DOI: https://doi.org/10.1002/14651858.CD003044.pub4
Butt NI, Butt UI, Kakar AA, Malik T, Siddiqui AM. Is lactulose plus rifaximin better than lactulose alone in the management of hepatic encephalopathy? Journal of College of Physicians and Surgeons Pakistan. 2018 Feb; 28(2): 115-7. doi: 10.29271/jcpsp.2018.02.115. DOI: https://doi.org/10.29271/jcpsp.2018.02.115
Acharya C and Bajaj JS. Current management of hepatic encephalopathy. Official Journal of the American College of Gastroenterology. 2018 Nov; 113(11): 1600-12. doi: 10.1038/s41395-018-0179-4. DOI: https://doi.org/10.1038/s41395-018-0179-4
Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology. 2008 Jun; 20(6): 506-11. doi: 10.1097/MEG.0b013e3282f3e6f5. DOI: https://doi.org/10.1097/MEG.0b013e3282f3e6f5
Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM: An International Journal of Medicine. 2010 Jan; 103(1): 9-16. doi: 10.1093/qjmed/hcp152. DOI: https://doi.org/10.1093/qjmed/hcp152
Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepatic Medicine: Evidence and Research. 2011 Dec; 22(3): 109-17. doi: 10.2147/HMER.S11988. DOI: https://doi.org/10.2147/HMER.S11988
Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therapeutic Advances in Gastroenterology. 2011 May; 4(3): 199-206. doi: 10.1177/1756283X11401774. DOI: https://doi.org/10.1177/1756283X11401774
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB et al. Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine. 2010 Mar; 362(12): 1071-81. doi: 10.1056/NEJMoa0907893. DOI: https://doi.org/10.1056/NEJMoa0907893
Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy. Alimentary Pharmacology and Therapeutics. 2014 Jul; 40(2): 123-32. doi: 10.1111/apt.12803. DOI: https://doi.org/10.1111/apt.12803
Saleem MZ, Saleem MH, Saleem H, Aasil MA. Rifaximin Effectiveness in Preventing the Recurrence Of Hepatic Encephalopathy Among Patients With Liver Cirrhosis. Pakistan Armed Forces Medical Journal. 2021 Aug; 71(4): 1296-99. doi: 10.51253/pafmj.v71i4.2481. DOI: https://doi.org/10.51253/pafmj.v71i4.2481
Ali B, Zaidi YA, Alam A, Anjum HS. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. Journal of College of Physicians and Surgeons Pakistan. 2014 Apr; 24(4): 269-73.
Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology. 2011 Aug; 23(8): 725-32. doi: 10.1097/MEG.0b013e32834696f5. DOI: https://doi.org/10.1097/MEG.0b013e32834696f5
Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018 Feb; 67(2): 700-10. doi: 10.1002/hep.29410. DOI: https://doi.org/10.1002/hep.29410
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S et al. l‐ornithine l‐aspartate in acute treatment of severe hepatic encephalopathy: a double‐blind randomized controlled trial. Hepatology. 2022 May; 75(5): 1194-203. doi: 10.1002/hep.32255. DOI: https://doi.org/10.1002/hep.32255
Aidrus F, Razzaque S, Siddiqui A, Kumar A, Ghaur MI. Therapeutic efficacy of l-ornithine l-aspartate in patients with hepatic encephalopathy. Pakistan Journal of Neurological Sciences. 2015; 10(3): 37-41.
Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology. 2019 Jan; 70(1): 172-93. doi: 10.1016/j.jhep.2018.06.024. DOI: https://doi.org/10.1016/j.jhep.2018.06.024
Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK et al. Branched‐chain amino acids for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews. 2017 May; 2015(9). doi: 10.1002/14651858.CD001939.pub3. DOI: https://doi.org/10.1002/14651858.CD001939.pub3
Ferenci, P.J.G.r., Hepatic encephalopathy. Gastroenterol Report. 2017 May; 5(2): 138-147. doi: 10.1093/gastro/gox013. DOI: https://doi.org/10.1093/gastro/gox013
Chandio SH, Fatima T, Hassan B, Jabeen S, Mumtaz H, Owais M et al. Role of probiotics in decreasing ammonia levels. Can they be used as a treatment of hepatic encephalopathy? 2020 Aug; 9(10): 1328-1337. doi: 10.20959/wjpr202010-18629.
Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews. 2017 Feb; (2): CD008716. doi: 10.1002/14651858.CD008716.pub3. DOI: https://doi.org/10.1002/14651858.CD008716.pub3
Patidar KR and Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metabolic Brain Disease. 2013 Jun; 28: 307-12. doi: 10.1007/s11011-013-9383-5. DOI: https://doi.org/10.1007/s11011-013-9383-5
Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982 Jan; 23(1): 1-7. doi: 10.1136/gut.23.1.1. DOI: https://doi.org/10.1136/gut.23.1.1
Mekky MA, Riad AR, Gaber MA, Abdel-Malek MO, Swifee YM. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. Arab Journal of Gastroenterology. 2018 Jun; 19(2): 76-9. doi: 10.1016/j.ajg.2018.06.001. DOI: https://doi.org/10.1016/j.ajg.2018.06.001
Rehman S, Fatima QU, Rehman S, Sami Z, Ali H, Saddiqa I. Comparison of current and emerging strategies for treating hepatic encephalopathy. The Professional Medical Journal. 2021 Nov; 28(12): 1705-10. doi: 10.29309/TPMJ/2021.28.12.6644. DOI: https://doi.org/10.29309/TPMJ/2021.28.12.6644
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
